Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

Conference Correspondent  - ESMO Highlights

Expression of programmed cell death ligand 1 (PD-L1) has been confirmed in human ovarian cancer cells, and preliminary evidence has supported the antitumor activity of anti–PD-1 therapies, like durvalumab, in treating ovarian cancers.1 In a phase 1/2, multicenter, open-label study, O’Cearbhaill and colleagues reported the preliminary safety and efficacy data of treating patients with platinum-resistant recurrent ovarian cancer with durvalumab in combination with standard-of-care pegylated liposomal doxorubicin (PLD).2

This study included a phase 1 3+3 dose escalation, with dose-limiting toxicity evaluated in one 28-day cycle (n = 6-18), and a phase 2 dose-expansion cohort (n = 41). Given that PLD has been reported to have a 6-month progression-free survival (PFS6) of 25%, the sample size of 41 evaluable patients is appropriately powered to test the null hypothesis of a PFS6 rate of ≤25% against the alternative hypothesis of a PFS rate of ≥45% at an alpha level of 0.05 (one-sided). Blood and tumor samples were also collected for assessment of correlative immunologic responses.

As of March 5, 2018, 40 female patients with a median age of 65 years (range, 32-83 years) were enrolled in phase 2 of the study. Each had received at least 1 dose of study therapy (PLD 40 mg/m2 + durvalumab 1500 mg once every 4 weeks) and were included in the safety analyses. The most frequently observed treatment-emergent adverse events (AEs, all causality), occurring in ≥25% of patients, were palmar-plantar erythrodysesthesia syndrome (PPES)/rash, stomatitis, fatigue, abdominal pain, nausea, pyrexia, and vomiting. Grade 3 treatment-related AEs in ≥2 patients included PPES/rash, stomatitis, lymphocyte count decreased, lipase increased, and anemia. As of the cutoff date, 33 patients had reached the time point for PFS6 assessment. Twelve patients were progression-free at 6 months, yielding a PFS6 of 47.7%. The remaining data will mature by July 2018, and further improvement in PFS6 may occur. At 6 months, 30 patients were still alive, resulting in a 6-month overall survival (OS) of 89%; at 12 months, 12 patients were alive (12-month OS, 65%).

The preliminary results reported here suggest that the combination of durvalumab and PLD has a tolerable safety profile and promising efficacy in women with platinum-resistant ovarian cancer. The final PFS6 and other translational end points are pending additional data.


References

  1. Lee J-M, et al. J Clin Oncol. 2017;35:2193-2202.
  2. O’Cearbhaill RE, et al. ESMO 2018. Abstract 945P.
Related Items
Adjuvant Abemaciclib plus Endocrine Therapy Game-Changer in High-Risk, HR-Positive, HER2-Negative Early Breast Cancer
Phoebe Starr
Web Exclusives published on November 3, 2020 in ESMO Highlights
Trabectedin/PLD versus Carboplatin/PLD in Recurrent Ovarian Cancer Progressing within 6-12 Months After Last Platinum Line
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Safety and Efficacy of XMT-1536 in Ovarian Cancer: Subgroup Analysis from a Phase 1 Expansion Study
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Maintenance Olaparib plus Bevacizumab for Newly Diagnosed High-Grade Ovarian Cancer: Second Progression-Free Survival
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Real-World Data on Platinum Therapy in High-Grade Serous Ovarian Cancer Patients Progressing After PARP Inhibitor Treatment
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Atezolizumab in Patients with Newly Diagnosed Stage III or Stage IV Ovarian Cancer
Conference Correspondent  published on September 23, 2020 in ESMO Highlights
Mirvetuximab Soravtansine in Combination with Carboplatin and Bevacizumab in Recurrent Ovarian Cancer
Conference Correspondent  published on September 22, 2020 in ESMO Highlights
Patient-Reported Outcomes in Patients Receiving Niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Trial
Conference Correspondent  published on September 22, 2020 in ESMO Highlights
Nivolumab versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients with Platinum-Resistant Ovarian Cancer: The NINJA Trial
Conference Correspondent  published on September 22, 2020 in ESMO Highlights
Individualized Starting Dose of Niraparib to Treat Platinum-Sensitive Recurrent Ovarian Cancer: The NORA Trial
Conference Correspondent  published on September 22, 2020 in ESMO Highlights
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.